Full Title: Pay-it-forward to improve influenza vaccine uptake and public engagement among children and older adults in China: three-arm quasi-experimental pragmatic trial

Short Title: Pay-it-forward innovation to improve influenza vaccination

Dan Wu[1,2,3,*,¶], Chenqi Jin[2,¶], Khaoula Bessame[1], Fanny Fong-Yi Tang[1,4], Jason J. Ong[1,5,6], Zaisheng Wang[2,7], Yewei Xie[2,8], Mark Jit[9], Heidi J. Larson[9], Tracey Chantler[10], Leesa Lin[9,11], Wenfeng Gong[12], Fan Yang[13], Fengshi Jing[2,14], Shufang Wei[2], Weibin Cheng[14], Yi Zhou[15,16], Nina Ren[14], Shuhao Qiu[17], Jianmin Bao[18], Liufen Wen[19], Qinlu Yang[20], Junzhang Tian[14], Weiming Tang[2,14,21,*,&], Joseph D. Tucker[1,2,21,&]

1. Department of Clinical Research, Faculty of Infectious and Tropical Diseases, London School of Hygiene and Tropical Medicine, London, UK

2. University of North Carolina at Chapel Hill Project-China, Guangzhou, China

3. West China School of Public Health, Sichuan University, Chengdu, China

4. Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong, China

5. Central Clinical School, Faculty of Medicine, Monash University, Melbourne, Australia

6. Melbourne Sexual Health Centre, Alfred Health, Melbourne, Australia

7. School of Health and Related Research, The University of Sheffield, Sheffield, UK.

8. Duke Global Health Institute, Duke University, North Carolina, U.S.

9. Faculty of Epidemiology and Population Health, London School of Hygiene and Tropical Medicine, London, UK

10. Faculty of Public Health and Policy, London School of Hygiene and Tropical Medicine, London, UK

11. Laboratory of Data Discovery for Health (D24H), Hong Kong Science Park, Hong

Kong, China

12. Beijing Representative Office, Bill & Melinda Gates Foundation, Beijing, China

13. Institute of Population Research, Peking University, Beijing, China

14. Guangdong Secondary Provincial General Hospital, Guangzhou, China

15. Zhuhai Center for Disease Control and Prevention, Zhuhai, China

16. Faculty of Medicine, Macau University of Science and Technology, Macau SAR, China

17. Vaccination Clinic, Yangshan Health Centre, Qingyuan, China

18. Fenghuang Community Health Service Centre, Zengcheng, China

19. Xinghua Community Health Service Centre, Guangzhou, China

20. Community representative, Guangzhou, China

21. Institute for Global Health and Infectious Diseases, School of Medicine, University of North Carolina at Chapel Hill, North Carolina, USA

[#] Denotes co-first authors

[§] Denotes co-senior authors

[*] Corresponding authors:

Dr Dan Wu, Department of Clinical Research, London School of Hygiene and Tropical Medicine, United Kingdom, dan.wu@lshtm.ac.uk

Dr Weiming Tang, University of North Carolina Project-China, and Guangdong Secondary Provincial General Hospital, Guangzhou, China, weiming_tang@med.unc.edu

Word count: 3900

ABSTRACT

Background: China has low seasonal influenza vaccination rates among children and older adults. This three-arm quasi-experimental pragmatic trial examined the effectiveness of a pay-it-forward intervention on influenza vaccination compared to standard of care (user-paid vaccination) and free vaccination strategies among children and older people in China. Pay-it-forward is a community-engaged social innovation in which people receive a free influenza vaccination from a local group and are then asked if they would like to donate financially and/or create a postcard message to promote vaccination among future individuals.

Methods and findings: We implemented the three study arms in three clinics (rural, suburban, urban) in Guangdong Province, China. A total of 225 children aged between 6 months and 8 years old and 225 older adults (60 years old or above) were recruited into the study. 75 children and 75 older adults were allocated to the standard of care arm, and equal numbers to the pay-it-forward arm and the free vaccination arm. Regression methods were used to compare influenza vaccine uptake (administrative records) and vaccine confidence (self-report) between the three arms.

Among 450 participants enrolled, 55/150 (36.7%) in the standard of care arm, 111/150 (74.0%) in the pay-it-forward arm, and 114/150 (76.0%) in the free vaccination arm received an influenza vaccine. People in the pay-it-forward arm were more likely to receive the vaccine compared to people in the standard of care arm (adjusted odd ratio (aOR)=7.9, 95%CI [3.2-19.7] among children; aOR=6.1, [2.8-13.2] among older adults). People in the pay-it-forward arm had higher confidence in influenza vaccine safety, importance and effectiveness compared to people in the standard of care arm. In the pay-it-forward arm, 107/111 (96.4%) of participants donated money for subsequent vaccinations and 19 of 60 invited (31.7%) created postcard messages.

Conclusions: Pay-it-forward was effective in improving influenza vaccine uptake and engagement among children and older adults. Our data have implications for pro-social interventions to enhance influenza uptake in the many countries where influenza vaccines are available for a fee.

Trial registration: ChiCTR2000040048

Keywords: influenza vaccine; social innovation; pragmatic trial.

Summary box

What is already known on this topic

- Seasonal influenza vaccination rates are low in many low- and middle-income countries.

- Effective community-engaged interventions to enhance influenza vaccination among at-risk populations are lacking.

- Lacking confidence in vaccines is an important determinant of the low influenza vaccine uptake.

What this study adds

- Our study suggests that pay-it-forward effectively improved influenza vaccine uptake and vaccine confidence among at-risk groups.

- Pay-it-forward generated a decent degree of community engagement and participant donations to support more people in resource-limited settings.

- The pragmatic nature of this trial in a less controlled condition informs evidence-based public health practices and innovative service delivery.

INTRODUCTION

In mainland China, an average of 10 people die from influenza-related illnesses each hour.[1] Influenza vaccination is the most effective way to prevent morbidity and mortality attributable to influenza.[2] Influenza vaccine is increasingly important during COVID-19 because it might help reduce risks of acquiring SARS-CoV-2 that causes COVID-19.[3, 4] The Chinese Center for Disease Control and Prevention (China CDC) guidelines recommend influenza vaccination for high-risk populations, including children aged below 5 years old and older adults (people older than 60 years old). However, influenza immunization policies widely vary,[5] and most cities in China do not provide free influenza vaccines to high-risk individuals. A meta-analysis reported less than one-fifth of children and older adults in China received an influenza vaccine in the past year.[6] These are true for many other low- and middle-income countries.[7]

There are several reasons for low influenza vaccination uptake in China.[6, 8] First, most people in China are unaware of influenza vaccination and many people are hesitant about vaccine safety and effectiveness.[9] Second, there is minimal public engagement in vaccinations.[10] Despite a strong rationale for public engagement, few programs engage the public regarding influenza vaccinations. Third, there are limited public resources to support influenza vaccination among high-risk populations. The influenza vaccine is largely not covered by mandatory health insurance schemes and, as a result, most people have to pay US$8.5-23.5 out-of-pocket to be vaccinated.[11] Innovative strategies are needed to improve influenza vaccine uptake.

Pay-it-forward is a community-engaged social innovation, which has an individual receive a free influenza vaccine and a hand-written postcard message co-created by previous participants informing them that someone else has paid for them to receive a free vaccine.[12] After they receive vaccination, they are asked if they would like to support the vaccination of a subsequent person (supplementary figures: Fig 1). Our previous pay-it-forward studies focused on increasing testing for sexually transmitted infections among sexual minorities. The pay-it-forward arm had a chlamydia and gonorrhea dual test uptake of 56% compared to 18% in the standard of care arm, where participants had to pay out-of-pocket.[13] [14] In addition, over 90% of participants donated to the rolling finance pool, [13, 14] and qualitative data showed that trust in health services improved among participants in the pay-it-forward arm.[15] This quasi-experimental pragmatic trial assessed the effectiveness of a pay-it-forward intervention to increase influenza vaccination uptake at three study sites among children (aged between 6 months and 8 years) and older adults (aged 60 or above) in comparison to free vaccination and the current standard of care (user-paid vaccination) in China.

METHODS

Study design and participants

Guangdong is a subtropical province in southern China with a population of over 120 million. In southern China, influenza is prevalent throughout the year.[16] In this study, we selected three research sites where influenza vaccination was only available on a for-fee basis. These three study sites were: a rural site (Yangshan County, Qingyuan City), a suburban site (Zengcheng District, Guangzhou City), and an urban site (Tianhe District, Guangzhou City). Study sites included community health centers (primary care facilities providing day-to-day healthcare in China) and vaccine centers.

Clinics were selected because they had sufficient influenza vaccines in stock and health professionals (nurses, doctors) familiar with influenza vaccination. This study consisted of three stages 1) co-creation of the intervention with stakeholders and engagement strategies during a three-day hackathon; 2) a feasibility pilot to inform the recruitment process and sample size calculations; and 3) a pay-it-forward quasi-experimental pragmatic trial to evaluate the effectiveness of the intervention (supplementary study protocol).

Patient and Public Involvement

Our team of three individuals joined a participatory hackathon from November 4-6, 2019, to co-create the pay-it-forward intervention. Co-creation is an iterative, bidirectional partnership between researchers and the public to develop new ideas.[17] Participants included potential end users, public health practitioners, health innovators, communication experts and vaccine experts. We mapped out the following elements of the study: 1) key stakeholders of the study; 2) potential user journeys; 3) engagement strategies; 4) behavioral mechanisms; and 5) donation strategies. Community engagement strategies used in this study included the following: inviting community members to design postcards relevant to influenza vaccination (Supplementary figures: Fig 2); working in partnership with a local older adult to develop a video to explain pay-it-forward; inviting study participants to write postcard messages during recruitment for future participants (Supplementary figures: Fig 3); and engaging local community staff in implementing the quasi-experimental study, including having one-to-two community staff members at each study site to help adjust recruitment and communication efforts to the local dialect.

Pilot

Before the quasi-experimental study, we carried out a feasibility pilot at the rural

study site from January to April 2020, which occurred during the social distancing period due to COVID-19 in China. The primary outcome of the study was influenza vaccination uptake. The purpose of the pilot was to finalize the pay-it-forward intervention process, assess feasibility, and estimate effect size to inform power calculations. This pilot demonstrated that, in the pay-it-forward arm, 90.9% (40/44) of participants received an influenza vaccine and 93% (37/40) of participants donated funds. Thirteen of 57 participants (22.3%) in the standard of care arm received a vaccine. The pilot data were then used to re-calculate the sample size.

Sample size calculation

We stratified sample size calculations by age groups, given the differences between children and older adults. The original sample size proposed was 600 (100 per age group per arm). Based on our pilot data, we anticipated that the proportion of vaccine uptake in the standard of care arm was 30%, and the proportion of vaccine uptake in the pay-it-forward arm was 80%, a significance level of 0.025; therefore, a sample size 100 (50 in the control arm and 50 in the intervention) for each age group would give us 90% power to test the within-group proportion difference in the primary outcome of vaccine uptake with a margin of 10%. We increased the sample size by 50% to allow for secondary analyses, resulting in a sample size of 75 for each age group in each arm. The free vaccine arm had the same sample size as the other two arms. This free vaccination arm was included because it has important implications for policy and global relevance to countries that already provide free influenza vaccinations. In sum, 225 children and 225 older adults would allow us sufficient power to test within-group differences in the study outcomes.

Quasi-experimental pragmatic trial

This trial evaluated the pay-it-forward intervention arm against both the standard of

care and a free vaccination program implemented in rural, suburban, and urban study sites. Each study site implemented all study arms and recruited participants were chronologically allocated (non-random) into the specified study arms because of practical considerations. Influenza vaccine services are usually available in China from September to April. Influenza vaccine availability is idiosyncratic at specific health facilities because of the periodical supply and procurement system in local settings. We allocated study arms to ensure a stable supply of vaccines (Supplementary figures: Fig 4: time-based recruitment). At each site, the standard of care arm was followed by the pay-it-forward arm. Despite discussions with health authorities and vaccine manufacturers, study sites encountered lapses in supply. The duration of time needed to recruit each study arm was related to the availability of vaccine and the number of people willing to participate.

The inclusion criteria for this study differed by age group and were determined according to China's national influenza vaccine guidelines.[18] Childhood eligibility criteria included the following: aged between six months and eight years old; no acute moderate or severe illnesses; eligible to receive an influenza vaccine based on clinical evaluation from a physician; has a legal guardian (e.g. a parent or grandparent) who lives in China and consents to participate in the study; and has not received an influenza vaccine in the past year. Older adult eligibility criteria included the following: ≥ 60 years old; no acute moderate or severe illness; eligible to receive an influenza vaccine based on clinical evaluation from a physician; capable of making informed decisions and consenting to participate in the study; and have not received an influenza vaccine in the past year. If multiple people in a family were eligible to join the study, we only allowed one person to join. All eligible children and older adults presenting to these sites were invited to participate by local medical staff

involved in the study during the recruitment periods.

Procedures

We were informed of vaccine availability by local study sites and commenced data collection in late September 2020. Among all potential participants visiting the selected clinics, health care workers assessed eligibility for the study based on inclusion criteria and introduced eligible participants to project staff.

Standard of care Participants recruited in the standard of care arm were provided with a brief introduction to the influenza vaccine by project staff using a pamphlet about influenza and influenza vaccination (Supplementary figures: Fig 5). They were then asked if they were willing to pay out of pocket at the standard market price (US$8.5-23.5 depending on the market price of vaccines provided at the clinic) to receive an influenza vaccination. Those who agreed to pay were screened for vaccination eligibility, and those without any contraindications received the vaccine.

Pay-it-forward Participants recruited in the pay-it-forward arm were provided with the same introductory pamphlet about influenza and influenza vaccination. Project staff then explained the pay-it-forward program, including its purpose, the opportunity to receive one dose of influenza vaccination for free, and the opportunity to donate money towards someone else's vaccine dose and write postcard messages (Supplementary figures: Fig 6). Participants were told that the normal price to receive an influenza vaccine, including administration fees were RMB 56(US$ 8.5) for children and 153(US$ 23.5) for adults, and that previous participants had donated money to cover the costs and had also created handwritten postcard messages for them.

If the participants decided to receive vaccination, they were asked prior to receiving the vaccination whether they were willing to donate any amount of money into a pool

of funds to support subsequent participants in receiving the same vaccine. They were assured that the donation was entirely voluntary, and any donation amount was acceptable and would not affect whether they received a vaccination or subsequent care. They were also invited to write anonymous postcard messages for future participants. A donation collection box was provided on-site for those who preferred to donate cash. A QR code using WeChat (a multifunctional social mobile app embedded with anonymous money transfer functions) was provided to those who chose to make online donations.

Donations were used to support the vaccination of subsequent participants and aggregated data on donation amounts were made publicly available on the website and WeChat newsletter of Social Entrepreneurship to Spur Health (a research hub in the UNICEF/UNDP/World Bank/WHO Special Programme for Research and Training in Tropical Diseases Social Innovation in Health Initiative). COVID-19 conditions at the rural site prevented participants from creating handwritten postcards during some periods of the trial.

Free vaccination Participants in the free vaccination arm were invited to participate using the same introductory pamphlet and were provided with free influenza vaccination. They did not receive any community-created messages about the pay-it-forward program.

Participation in each arm was voluntary and anonymous. After introducing the intervention, all participants were asked to complete a short, self-administered online questionnaire to collect information about sociodemographic characteristics and attitudes towards influenza vaccines (supplementary questionnaire). Vaccine confidence in importance, safety, and effectiveness were measured using survey items adapted to assess influenza vaccine confidence in China.[19, 20] Those who had

difficulty reading the questionnaire were assisted by the project and healthcare staff on-site. A small gift worth around RMB10 (US$1.5) was given to each participant after completing the questionnaire survey.

Data collection

Data collection was conducted from September 2020 to March 2021. The study collected the following information: administrative data recorded by research staff using a standard information tracking sheet including the number of invited and participating individuals, the number of participants who received the vaccine, the number of individuals who donated and the amount donated in the pay-it-forward arm, as well as survey data through a self-administered survey instrument. Administrative and survey data were linked using numerical IDs. We collected information about the number of participants in the pay-it-forward arm who donated and corresponding donation amount, and those who created a postcard text for subsequent people. Costs associated with each arm were collected for an economic evaluation.

Study outcomes

The primary outcome was influenza vaccine uptake ascertained by administrative records. Secondary outcomes included self-reported vaccine confidence, defined as public trust in the vaccine safety, importance and effectiveness, using a standard vaccine confidence scale [21] and economic evaluation.

Data analysis

Descriptive analyses were conducted to summarize each arm's sociodemographic and behavioral characteristics, participation rate, and vaccination rate. We used a Chi-squared test to investigate differences in vaccination uptake between the standard of care, pay-it-forward, and free vaccination arms. We ran multivariable logistic regression to examine the association between vaccine uptake and interventions after

adjusting for age, sex, study sites, education, occupation, income, and marital status.
We also examined the association between vaccine confidence and interventions using
multivariable regression. We summarized the participants' donations in the pay-it-
forward arm, and compared proportions of participants between rural, suburban and
urban sites who contributed US$7.6 (close to a child vaccine cost) or more. All data
were analyzed using SPSS Version 25 and STATA 17.

Cost Analysis

A decision tree was built to calculate and compare the costs and outcomes of the three
influenza vaccination arms examined in the quasi-experimental study. We evaluated
the costs of all three arms using a micro-costing approach and reported this in 2020
USD. The costs of implementing each strategy were estimated using invoices, onsite
staff's self-reporting the wages of healthcare workers, and estimated opportunity costs
of community staff's time (supplementary costs file). Additional costs in the pay-it-
forward arm related to volunteer time, as well as recruitment and donation process
associated with the start-up and recurrent costs. Financial costs were obtained from
subtracting donation contributions from the total economic cost. The analysis was
performed from the perspective of the healthcare provider, the Guangdong
Department of Health. The time horizon considered was the duration of the seasonal
influenza vaccination program. We reported the total economic and financial cost for
each arm, the cost per person vaccinated, and the incremental cost-effectiveness ratios.

RESULTS

In total, 254 children's caregivers and 262 older adults were approached at the three
study sites (Fig 1). Forty-six people declined to participate, and 30 had recently
received the influenza vaccine. In total, 450 participants were enrolled and completed

the survey, including 150 in the pay-it-forward arm, 150 in the free vaccine arm, and 150 in the standard of care arm. All 450 responses were screened for completeness and included in the final statistical analyses.

Fig 1: Quasi-experimental study flowchart

Characteristics of caregivers of children and older adult participants were similar across the three arms (Table 1). Regarding the primary outcome of vaccine uptake, 111 (74.0%) of 150 pay-it-forward participants, 114 (76.0%) of 150 participants offered free vaccination, and 55 (36.7%) of 150 participants in the standard of care arm received influenza vaccination (χ^2 test p<0.001; Fig 2; supplementary table 1). Among children, the pay-it-forward arm had an uptake rate of 88.0% (66/75) compared to 53.3% (40/75) in the standard of care arm. Among older adults, the pay-it-forward arm had an uptake rate of 60.0% (45/75) compared to 20.0% (15/75) in the standard of care arm. Differences in uptake between the pay-it-forward and standard of care arms remained statistically significant for both groups after adjusting for study

site and educational level (Supplementary tables: table 1). Uptake in the pay-it-

forward and free vaccination arms were not significantly different for both age groups.

Fig 2: Influenza vaccine uptake rates by intervention arms and age group in Guangdong Province, China, 2020-2021 (N=450)

Table 1: Sample characteristics of recruited child caregivers and older adults in Guangdong Province, China, 2021 (N=450)

	Child caregiver group				The older adult group			
	Standard of care (N=75)	Pay-it-forward (N=75)	Free vaccination (N=75)	p value	Standard of care (N=75)	Pay-it-forward (N=75)	Free vaccination (N=75)	p value
Age	35.91 (10.3)	36.71 (9.7)	36.95 (8.9)	0.357	69.53 (6.4)	66.52 (6.7)	68.59 (6.0)	0.988
Sex				0.975				0.489
Men	17 (22.7)	16 (21.3)	17 (22.7)		20 (26.7)	27 (36.0)	23 (30.7)	
Women	58 (77.3)	59 (78.7)	58 (77.3)		55 (73.3)	48 (64.0)	52 (69.3)	
Education				0.005				0.459
Elementary school or below	8 (10.7)	4 (5.3)	4 (5.3)		33 (44.0)	26 (34.7)	29 (38.7)	
Middle school	45 (60.0)	26 (34.7)	35 (46.7)		31 (41.3)	42 (56.0)	35 (46.7)	
Undergraduate or above	22 (29.3)	45 (60.0)	36 (48.0)		11 (14.7)	7 (9.3)	11 (14.7)	
Occupation				0.281				0.785
Unemployed	20 (26.7)	21 (28.0)	22 (29.3)		53 (70.7)	58 (77.3)	60 (80.0)	
Peasant	1 (1.3)	1 (1.3)	5 (6.7)		19 (25.3)	15 (20.0)	13 (17.3)	
Employed	54 (72.0)	53 (70.7)	48 (64.0)		3 (4.0)	2 (2.7)	2 (2.7)	
Annual income (USD)				0.963				0.664
0-1860	19 (25.3)	23 (30.7)	20 (26.7)		38 (50.7)	28 (37.3)	28 (37.3)	
1860-9300	22 (29.3)	24 (32.0)	21 (28.0)		29 (38.7)	36 (48.0)	37 (49.3)	
9300-1,8600	20 (26.7)	16 (21.3)	19 (25.3)		7 (9.3)	10 (13.3)	8 (10.7)	
>1,8600	14 (18.7)	12 (16.0)	15 (20.0)		1 (1.3)	1 (1.3)	2 (2.7)	
Marital status				0.658				0.149
Single, divorced, separated or widowed	4 (5.3)	4 (5.3)	2 (2.7)		20 (26.7)	20 (26.7)	11 (14.7)	
Married or living with a partner	71 (94.7)	71 (94.7)	73 (97.3)		55 (73.3)	55 (73.3)	64 (85.3)	

Table 2 suggests that people in the pay-it-forward arm were more likely to receive the vaccine compared to people in the standard of care arm (adjusted odd ratio (aOR)=7.9, 95%CI [3.2-19.7] among children; aOR=6.1, [2.8-13.2] among older adults). Free-of-charge vaccination participants had greater odds than those in the standard of care arms to receive a vaccination (aOR=5.5, [2.4-12.6] among children; aOR=9.1, [4.2-20.0] among older adults).

Table 2: Multivariable logistic regression to compare vaccine uptake rates of three arms by age groups in Guangdong Province, China, 2020-2021 (N=450)

Arms/Age groups	Children (N=225)		Older adults (N=225)	
	COR (95% CI)	AOR (95% CI)	COR (95% CI)	AOR (95% CI)
Standard of care	Ref	Ref	Ref	Ref
Pay-it-forward	6.42 (2.80, 14.73) p<0.0001	7.93 (3.20, 19.68) p<0.0001	6.00 (2.89, 12.46) p<0.0001	6.07 (2.81, 13.15) p<0.0001
Free vaccine	5.09(2.324, 11.153) P<0.0001	5.48 (2.38, 12.63) p<0.0001	8.00 (2.81, 16.81) p<0.0001	9.104 (4.15, 19.96) p<0.0001

AOR: Model adjusted for age, sex, study sites, education level, occupation, income, and marital status.

Our study also generated public engagement in several important ways. Six postcard designs were developed by the community and subsequently used to explain the pay-it-forward system to potential participants. Pay-it-forward participants contributed to the development of influenza vaccination materials, and 19/60 (31.7%) people wrote postcard messages for subsequent participants. Most handwritten messages expressed general good wishes. In addition, we co-created a video and one local older adult contributed to this video design, implementation, and evaluation (supplementary video link).

Among 435 who provided information on the secondary outcome of vaccine confidence, confidence levels in the safety, importance and effectiveness were high (75.9%, 80.7% and 73.8%, respectively). People in the pay-it-forward arm had higher confidence in influenza vaccine safety compared to people in the standard of care arm (83.3 vs 67.4%; aOR=2.25, [1.27- 4.01], with a greater level than that in the free vaccination arm (76.7%) (Table 3). Similar trends were observed in confidence in vaccine effectiveness and importance.

Table 3: Association between study arm and vaccine confidence in influenza vaccine in Guangdong Province, China, 2020-2021 (N=435)

Study arm	Vaccine confidence - Safety				Vaccine confidence - Importance				Vaccine confidence – Effectiveness			
	Total N(%)	cOR[3] (95% CI)[6]	aOR[4] (95% CI)	P value[5]	Total N(%)	cOR (95% CI)	aOR (95% CI)	P value	Total N(%)	cOR (95% CI)	aOR (95% CI)	P value
Standard of care[1]	95(67.4)	Reference	Reference	0.02	97(68.8)	Reference	Reference	0.004	88(62.4)	Reference	Reference	0.004
Free vaccine	115(76.7)	1.59 (0.95-1.67)	1.54 (0.91- 2.63)		127(84.7)	2.50 (1.42-4.43)	2.48 (1.38-4.52)		111(74.0)	1.71 (1.04-2.82)	1.71 (1.01-2.85)	
Pay-it-forward[2]	120(83.3)	2.42 (1.38-4.25)	2.25 (1.27- 4.01)		127(88.2)	3.39 (1.82-6.29)	3.15 (1.66-6.05)		122(84.7)	3.34 (1.89-5.89)	3.19 (1.75-5.64)	

Footnote:

[1] User-paid influenza vaccine was the standard of care.

[2] In addition to donated influenza vaccines, the pay-it-forward study condition received positive postcard messages and the option to support the vaccination of other members of the community through voluntary monetary donations or similar postcards.

[3] cOR = crude odds ratio

[4] aOR = adjusted odds ratio

[5] P-value obtained using Likelihood Ratio Tests

[6] CI = confidence interval

[7] Estimates were adjusted for age, sex, occupation, education level, income level

The other secondary outcome focused on costs associated with each arm. Among 111

participants in the pay-it-forward arm who received the influenza vaccine, 107 (96.4%)

donated money, with a total contribution of US$597.62. Donations covered 36.0% of

vaccination costs in the pay-it-forward arm. The median donation was US$4.6. Only 30% of

donors in the rural site contributed US$7.6 or more compared to 61.9% in the suburban and

40.0% in urban sites (supplementary Fig 7 and supplementary table 2).

The total financial cost of implementing an influenza vaccination intervention for children

and older adults was US$2,725 for the standard of care arm, US$4,477 for the pay-it-forward

arm, and US$4,665 for the free vaccination arm. The incremental cost for each treatment arm,

the incremental number of people vaccinated, and the incremental cost-effectiveness ratios

(ICERs) based on financial and economic costs are shown in Table 4 and the supplementary

costs file. Based on the ICER obtained from comparing pay-it-forward to the standard of care,

the financial cost required per additional person vaccinated was US$31.29. The financial cost

required per additional person vaccinated was US$62.67 when comparing free vaccination

arm to pay-it-forward. When economic costs are considered, the economic cost of

implementing an influenza vaccination intervention for children and older adults was

US$3,557 for standard of care, US$5,062 for pay-it-forward, US$4,665 for the free

vaccination arm.

Table 4: Economic evaluation of the influenza vaccine strategies

Treatment group	Financial cost (USD)	Incremental cost (USD)	Number of people vaccinated	Incremental number of people vaccinated	ICER (USD per person vaccinated)
Standard of care	2725		55		
Pay-it-forward	4477	1752	111	56	31.29
Free vaccination	4665	188	114	3	62.67
Treatment group	Economic cost (USD)	Incremental cost (USD)	Number of people vaccinated	Incremental number of people vaccinated	ICER (USD per person vaccinated)

Standard of care	3557		55		
Free vaccination	4665	1109	114	59	18.79
Pay-it-forward	5062	397	111	-3	Dominated

ICER = incremental cost-effectiveness ratio; USD = United States dollars (2020)

DISCUSSION

Our study contributes to the literature by determining the effectiveness of a social innovation using a quasi-experimental study, developing new methods for influenza vaccination public engagement, and identifying a new method to enhance influenza vaccine uptake. Our data suggest that the pay-it-forward strategy may increase influenza vaccine uptake among high-risk individuals compared to the current self-pay strategy for vaccination. This strategy substantially increased vaccine uptake compared to the standard of care, elicited financial contributions, improved vaccine confidence, and co-created participatory messages.

We found that children and older adults who took part in pay-it-forward had higher influenza vaccine uptake than they did if they needed to self-pay for vaccination. This finding is consistent with previous intervention studies using pay-it-forward to improve health services uptake.[13, 14] The effect of pay-it-forward might be related to the reduced costs associated with vaccination, enhanced public engagement, or both. The pay-it-forward arm had a similar vaccination rate to that of the free vaccine arm. This suggests that asking participants to make some financial contribution to support the vaccination of subsequent participants did not deter them from participating.

We also observed that, among those enrolled in the pay-it-forward arm, nearly all voluntarily donated to support another person in receiving an influenza vaccine, including those with a low annual income from a study site in a poor rural area. Compared to standard of care, the pay-it-forward arm had a higher financial cost, but increased the number of people vaccinated. The incremental financial cost per person vaccinated was lower than the median cost (US $50.78) per additional enrollee vaccinated from a systematic review published in 2018.[22]

Donations collected using a pay-it-forward system can support more individuals in receiving influenza vaccine services and can potentially reduce the financial burden for local governments. Pay-it-forward could also potentially transition from out-of-pocket payments to government-funded influenza vaccine programs.

Pay-it-forward has additional social benefits; it generated many messages aimed at driving influenza vaccine uptake. This is a rare example of public engagement in an influenza vaccination program.[10] Public engagement is central to the success of public health programs; given that some engagement methods (in-person events) could facilitate influenza transmission,[23] it is especially important to identify public engagement methods that are safe and effective. Engaging the community in vaccination services through cultivating kindness and reciprocity may also strengthen community solidarity, and increase confidence in vaccine services.[15, 24]

The study has several limitations. First, although our study was implemented after COVID-19 lockdowns were lifted, all sites were heavily focused on COVID-19 prevention, vaccination, and related activities. This caused some delays in recruitment despite the availability of influenza vaccines. At the same time, this demonstrates the feasibility of pay-it-forward. Second, we examined people from only three sites. However, our sites all had a high influenza prevalence, included different settings (rural, suburban, urban), and reflected common pathways for vaccination in China. Third, our study did not capture granular data on implementation. Future effectiveness research to examine different pay-it-forward implementation strategies is needed to differentiate effective components and determine optimal pay-it-forward practices. Finally, this was a quasi-experimental study and did not use randomization. However, quasi-experimental methods are commonly adopted when randomization is difficult in clinical and public health settings.[25] Also the study was designed to make contextual backgrounds between the three arms as similar as possible to

control potential confounders. In addition, our previous pay-it-forward quasi-experimental study results [13] were similar to a subsequent randomized controlled trial. [14]

Our study has implications for research, implementation, and policy. From a research perspective, this study expands the limited literature on public engagement in influenza vaccine programs. It demonstrates how social innovation can engage key communities in the implementation process and build confidence in influenza vaccination. This might help address vaccine hesitancy and anti-vaccine movements. The success of the pay-it-forward initiative and different donation levels across three study sites shows the potential to mobilize financial resources between areas with different economic status (e.g., mobilize financial resources from economically better-off areas to subsidize essential preventive services for people in more impoverished areas). Randomized controlled trials and qualitative research are needed to better understand the implementation of this system and integrate this intervention within health systems.

Pay-it-forward may be particularly relevant in the large number of countries that charge fees for influenza vaccines, which contributes to disparities in influenza vaccine uptake. Developing pay-it-forward programs could help financially support expanded influenza vaccination programs in these settings while also generating community-engaged messages. Further pay-it-forward influenza vaccination research could help explore how to expand vaccine programs in a more equitable and pro-social manner.

DATA AVAILABILITY

Requests for data by researchers with proposed use of the data can be made to the corresponding author with specific data needs, analysis plans and dissemination plans. Those requests will be reviewed by a study steering committee and the study sponsor for release upon publication. Original data and analysis codes used to generate primary findings of the paper are attached as a zip file for the editor and reviewers.

ETHICS APPROVAL

TRANSPARENCY STATEMENT

We affirm that the manuscript is an honest, accurate, and transparent account of the study being reported; that no important aspects of the study have been omitted; and that any discrepancies from the study as originally planned (and, if relevant, registered) have been explained.

FUNDING SUPPORT

ACKNOWLEDGEMENT

We appreciate support from Dr. David Sarley from Bill & Melinda Gates Foundation for his contribution and support to the early development of the intervention package. We are grateful for comments from Dr. Jing Li at West China School of Public Health Sichuan University to help improve clarity of the paper. We thank Huipeng Liao, Yafei Si, Xu Chen, Xiaolin Qiu, Yuxin Ni, Yuan Xiong, Ruoyu Zhu, Jie Fan, Yumeng Du from University of North Carolina at Chapel Hill Project-China, Fiona Sun and Kaiyi Han from Faculty of

Public Health and Policy, London School of Hygiene and Tropical Medicine for their help with questionnaire instrument development, data collection, video production, data visualization and interpretation.

AUTHOR CONTRIBUTIONS

DW, WT and JDT conceived the idea and designed the study. CJ, ZW, YX, NR, SQ, JB, LW implemented the study and collected data. CJ, KB, FFT, and FJ cleaned and analyzed data, and generated figures, tables to present findings of the paper. JJO, MJ, HJL, TC, LL, WG, and FY provided expert advice on designing the study, analyzing data and interpreting results. SW, WC, YZ, QY and JT coordinated local resources, provided community and stakeholder perspectives to refine the study design, and produced communication materials. DW and CJ wrote the first draft of the paper and all co-authors provided constructive comments and edited the manuscript. All authors have seen and approved the final version of the article.

CONFLICTS OF INTEREST

None.

REFERENCES

1. Li L, Liu Y, Wu P, Peng Z, Wang X, Chen T, et al. Influenza-associated excess respiratory mortality in China, 2010–15: a population-based study. The Lancet Public Health. 2019;4(9):e473-e81.

2. Mameli C, Cocchi I, Fumagalli M, Zuccotti G. Influenza vaccination: effectiveness, indications, and limits in the pediatric population. Frontiers in pediatrics. 2019;7:317.

3. Conlon A, Ashur C, Washer L, Eagle KA, Bowman MAH. Impact of the influenza vaccine on COVID-19 infection rates and severity. American journal of infection control. 2021.

4. Candelli M, Pignataro G, Torelli E, Gullì A, Nista EC, Petrucci M, et al. Effect of influenza vaccine on COVID-19 mortality: a retrospective study. Internal and Emergency

Medicine. 2021:1-7.

5.   Principi N, Camilloni B, Esposito S, Group EVS. Influenza immunization policies: Which could be the main reasons for differences among countries? Human vaccines & immunotherapeutics. 2018;14(3):684-92.

6.   Wang Q, Yue N, Zheng M, Wang D, Duan C, Yu X, et al. Influenza vaccination coverage of population and the factors influencing influenza vaccination in mainland China: A meta-analysis. Vaccine. 2018;36(48):7262-9. Epub 2018/10/21. doi: 10.1016/j.vaccine.2018.10.045. PubMed PMID: 30340886.

7.   Ortiz JR, Neuzil KM. Influenza Immunization in Low- and Middle-Income Countries: Preparing for Next-Generation Influenza Vaccines. The Journal of Infectious Diseases. 2019;219(Supplement_1):S97-S106. doi: 10.1093/infdis/jiz024.

8.   Wang J, Sun D, Abudusaimaiti X, Vermund SH, Li D, Hu Y. Low awareness of influenza vaccination among pregnant women and their obstetricians: a population-based survey in Beijing, China. Human vaccines & immunotherapeutics. 2019;15(11):2637-43.

9.   Song Y, Zhang T, Chen L, Yi B, Hao X, Zhou S, et al. Increasing seasonal influenza vaccination among high risk groups in China: Do community healthcare workers have a role to play? Vaccine. 2017;35(33):4060-3. doi: https://doi.org/10.1016/j.vaccine.2017.06.054.

10.   Thomas RE, Lorenzetti DL. Interventions to increase influenza vaccination rates of those 60 years and older in the community. The Cochrane database of systematic reviews. 2018;5(5):CD005188-CD. doi: 10.1002/14651858.CD005188.pub4. PubMed PMID: 29845606.

11.   NA. How much does an influenza vaccine (trivalent and quadrivalent) cost? : Wuhan.com; 2020 [cited 2021 16 September, 2021].

12.   Tang W, Wu D, Yang F, Wang C, Gong W, Gray K, et al. How kindness can be contagious in healthcare. Nature Medicine. 2021;27(7):1142-4. doi: 10.1038/s41591-021-

01401-x.

13.   Li KT, Tang W, Wu D, Huang W, Wu F, Lee A, et al. Pay-it-forward strategy to enhance uptake of dual gonorrhea and chlamydia testing among men who have sex with men in China: a pragmatic, quasi-experimental study. The Lancet Infectious diseases. 2019;19(1):76-82. Epub 2018/12/28. doi: 10.1016/S1473-3099(18)30556-5. PubMed PMID: 30587296; PubMed Central PMCID: PMCPMC6347395.

14.   Yang F, Zhang TP, Tang W, Ong JJ, Alexander M, Forastiere L, et al. Pay-it-Forward Gonorrhea and Chlamydia Testing Among Men Who Have Sex With Men in China: A Randomized Controlled Trial. The Lancet Infectious diseases. 2020.

15.   Li KT, Huang W, Tang W, Wu F, Zhao Y, Wu D, et al. A Secondary Mixed Methods Analysis of a Pay-it-Forward Gonorrhea/Chlamydia Testing Program Among Men Who Have Sex With Men in China. Sexually transmitted diseases. 2020;47(6):395-401.

16.   Shu Y-L, Fang L-Q, de Vlas SJ, Gao Y, Richardus JH, Cao W-C. Dual seasonal patterns for influenza, China. Emerging infectious diseases. 2010;16(4):725-6. doi: 10.3201/eid1604.091578. PubMed PMID: 20350403.

17.   Finley N, Swartz TH, Cao K, Tucker JD. How to make your research jump off the page: Co-creation to broaden public engagement in medical research. PLOS Medicine. 2020;17(9):e1003246. doi: 10.1371/journal.pmed.1003246.

18.   China CDC. Technical guideline for influenza vaccination in China Beijing: China CDC; 2018 [cited 2019 19 Nov]. Available from: http://www.chinacdc.cn/jkzt/crb/bl/lxxgm/jszl_2251/201809/t20180921_194050.html.

19.   Wei Z, Sun X, Yang Y, Zhan S, Fu C. Seasonal influenza vaccine hesitancy profiles and determinants among Chinese children's guardians and the elderly. Expert Review of Vaccines. 2021:1-10.

20.   de Figueiredo A, Simas C, Karafillakis E, Paterson P, Larson HJ. Mapping global

trends in vaccine confidence and investigating barriers to vaccine uptake: a large-scale retrospective temporal modelling study. The Lancet. 2020;396(10255):898-908.

21.   Larson HJ, De Figueiredo A, Xiahong Z, Schulz WS, Verger P, Johnston IG, et al. The state of vaccine confidence 2016: global insights through a 67-country survey. EBioMedicine. 2016;12:295-301.

22.   Anderson LJ, Shekelle P, Keeler E, Uscher-Pines L, Shanman R, Morton S, et al. The Cost of Interventions to Increase Influenza Vaccination: A Systematic Review. American journal of preventive medicine. 2018;54(2):299-315. Epub 2018/01/18. doi: 10.1016/j.amepre.2017.11.010. PubMed PMID: 29362167.

23.   Shobugawa Y, Fujiwara T, Tashiro A, Saito R, Kondo K. Social participation and risk of influenza infection in older adults: a cross-sectional study. BMJ open. 2018;8(1):e016876-e. doi: 10.1136/bmjopen-2017-016876. PubMed PMID: 29371265.

24.   Konrath S, Brown S. The effects of giving on givers. Health and social relationships: The good, the bad, and the complicated. Washington, DC, US: American Psychological Association; 2013. p. 39-64.

25.   Eliopoulos GM, Harris AD, Bradham DD, Baumgarten M, Zuckerman IH, Fink JC, et al. The use and interpretation of quasi-experimental studies in infectious diseases. Clinical infectious diseases. 2004;38(11):1586-91.

Supplementary video link

https://drive.google.com/file/d/1vXEVpVSi_x_8P8bva58qL_Wqh7u5bRRB/view?usp=sharing

Supplementary Fig 1: Pay-it-forward model overview

Supplementary Fig 2 postcard example

Supplementary Fig 3: translated hand-written postcard messages

Supplementary Fig 4 Time-based recruitment for the three study arms at three study sites[1]

* Each site only used one arm at a single time period and all three sites had standard-of-care arm followed directly by pay-if-forward arm.

Footnote: The recruitment in Yangshan was spaced out because of occasional stock outs. The lengths of time for the three arms at the study sites varied due to variations in patient volume and recruitment pace.

Supplementary Fig 5: Introduction to influenza (English translation).

Supplementary Fig 6: pay-it-forward pamphlet (English translation).

Supplementary Fig 7: Distribution of donation amounts by study site (n=107)

Note: 1 US$=6.59 RMB

Supplementary table 1 Proportion differences in influenza vaccination rates between the three study arms by age groups in Guangdong Province, China, 2020-2021 (N=450)

	Children N=225		Older adults N=225	
Uptake (n,%)		**P value**		**P value**
		<0.0001		**<0.0001**
Standard of care	40 (53.3)		15 (20)	
Pay-it-forward	66 (88)		45 (60)	
Free vaccine	64 (85.3)		50 (66.7)	
Study arms	**Crude proportion difference (95%CI)**	**P value**	**Crude proportion difference (95%CI)**	**P value**
Pay-it-forward vs Standard of care	34.7 (21.2, 48.1)	<0.0001	40.0 (25.7, 54.3)	<0.0001
Free vaccine vs Standard of care	32.0 (18.2, 45.8)	<0.0001	46.7 (32.7, 60.7)	<0.0001
Pay-it-forward vs Free vaccine	2.7 (-8.2, 13.5)	0.81	-6.7 (-22.1, 8.7)	0.50
Adjusting study site	**Adjusted proportion difference (95%CI)**	**P value**	**Adjusted proportion difference (95%CI)**	**P value**
Pay-it-forward vs Standard of care	34.7 (21.4, 47.9)	<0.0001	40.0 (26.3, 53.7)	<0.0001

Free vaccine vs Standard of care	32.0 (18.4, 45.6)	<0.0001	46.7 (33.0, 60.3)	<0.0001
Pay-it-forward vs Free vaccine	2.7 (-7.7, 13.0)	0.80	-6.7 (-21.3, 8.0)	0.476
Adjusting education level				
Pay-it-forward vs Standard of care	36.3 (22.1, 50.5)	<0.0001	41.1 (27.1, 55.1)	<0.0001
Free vaccine vs Standard of care	36.3 (22.9, 50.0)	<0.0001	45.8 (31.9, 59.7)	<0.0001
Pay-it-forward vs Free vaccine	3.3 (-7.9, 14.5)	0.81	-5.6 (-20.6, 9.3)	0.486

Supplementary table 2: Distribution of donation status and participants with a donation of 50 RMB or above by study site

Characteristic	Rural (n=50)	Suburban (n=50)	Urban (n=50)	p-value*
Donation status (n=150)				
- *Donated*	80.0 (40)	84.0 (42)	50.0 (25)	<0.001
- *Did not donate*	20.0 (10)	16.0 (8)	50.0 (25)	
Characteristic	Rural (n=40)	Suburban (n=42)	Urban (n=25)	p-value*
Donation amount (n=107)				
- *<50 RMB*	70.0 (28)	38.1 (16)	60.0 (15)	0.013
- *>=50 RMB*	30.0 (12)	61.9 (26)	40.0 (10)	

Note: US$ 1 = RMB 6.59

Supplementary costs file

Title: Pay-it-forward to improve influenza vaccine uptake and public engagement among children and older adults in China: A quasi-experimental pragmatic study

Costs file Table 1: *Unit costs (in 2020 USD) and frequency of vaccine use*

Intervention	Cost item	Unit cost	Resource use	Source
Pay-it-forward		Staff wage per hour (USD/hour)*		
• Start-up costs				
	Time designing postcards to be written on by participants in the PIF programme†	7.47	1 x 5 hr	Personal communication with research staff
	Time of research fellow participating in preparatory workshop†	12.7	1 x 5 hr	Personal communication with research staff
	Time of research assistant participating in preparatory workshop†	7.47	1 x 5 hr	Personal communication with research staff
	Time of nurses participating in preparatory workshop	4.81	3 x 1 hr	Personal communication with research staff China Social Welfare Foundation (12)
	Time of clinic coordinators participating in preparatory workshop	4.81	3 x 1 hr	Personal communication with research staff China Social Welfare Foundation(12)

- Fixed costs

Vaccinators (doctors) for the three clinics	11.07	3 x 70 hr	China Social Welfare Foundation (12)

- Recurrent costs

Time of nurses in recruiting patients to join the PIF programme††	4.81	3 x 25 hr	Personal communication with research staff China Social Welfare Foundation (12)
Time of clinic coordinators in performing administrative work for the PIF programme††	4.81	3 x 25 hr	Personal communication with research staff China Social Welfare Foundation (12)

	Cost per vaccine (USD)		
Cost of adult vaccines in Yangshan#	22.9	41	Health clinic reimbursement invoices
Cost of adult vaccine in Zengcheng	22.9	17	Health clinic reimbursement invoices
Cost of child vaccine in Zengcheng	8.38	25	Health clinic reimbursement invoices
Cost of adult vaccine in Tianhe#	12.2	28	Health clinic reimbursement invoices

		Cost per item / batch (USD)		
	Introductory pamphlets for the PIF programme (batch cost)	29.0	1	Project research staff invoices
	Ballpoint pens (for writing messages on PIF postcards) (batch cost)	2.25	1	Project research staff invoices
	Cost of printing postcards (batch cost)	7.41	1	Project research staff invoices
	Surgical gloves	0.075	222	Personal communication with research staff

Intervention	Cost item	Unit cost	Resource use	Source
Standard-of-care		Staff wage per hour (USD/hour)*		
• Start-up costs	*Time of nurses participating in preparatory workshop*	4.81	3 x 1 hr	China Social Welfare Foundation (12)
	Time of clinic coordinators participating in preparatory workshop	4.81	3 x 1 hr	China Social Welfare Foundation (12)

- Fixed costs

	Vaccinators for the three clinics	11.07	3 x 70 hr	China Social Welfare Foundation (12)

- Recurrent costs

	Time of nurses in recruiting patients to receive seasonal influenza vaccination††	4.81	3 x 12.5 hr	Personal communication with research staff China Social Welfare Foundation (12)
	Time of clinic coordinators in performing administrative work for influenza vaccination††	4.81	3 x 12.5 hr	Personal communication with research staff China Social Welfare Foundation (12)

		Cost per vaccine (USD)		
	Cost of adult vaccines in Yangshan#	22.9	15	Health clinic reimbursement invoices
	Cost of adult vaccine in Zengcheng	22.9	5	Health clinic reimbursement invoices
	Cost of child vaccine in Zengcheng	8.38	14	Health clinic reimbursement invoices
	Cost of adult vaccine in Tianhe#	12.2	21	Health clinic reimbursement invoices

		Cost per item (USD)		
	Surgical gloves	0.075	110	Personal communication with research staff

Intervention	Cost item	Unit cost	Resource use	Source

Free vaccination

- Start-up costs

		Staff wage per hour (USD/hour)*		
	Time of nurses participating in preparatory workshop	4.81	3 x 1 hr	Personal communication with research staff China Social Welfare Foundation (12)
	Time of clinic coordinators participating in preparatory workshop	4.81	3 x 1 hr	Personal communication with research staff China Social Welfare Foundation (12)

- Fixed costs

	Vaccinators for the three clinics	11.07	3 x 70 hr	China Social Welfare Foundation (12)

- Recurrent costs

	Time of nurses in recruiting patients to join the PIF programme††	4.81	3 x 12.5 hr	Personal communication with research staff China Social Welfare Foundation (12)
	Time of clinic coordinators in performing administrative work for the PIF programme††	4.81	3 x 12.5 hr	Personal communication with research staff China Social Welfare Foundation (12)
		Cost per vaccine (USD)		
	Cost of adult vaccines in Yangshan#	22.9	42	Health clinic reimbursement invoices
	Cost of adult vaccine in Zengcheng	22.9	13	Health clinic reimbursement invoices

Cost of child vaccine in Zengcheng	8.38	18	Health clinic reimbursement invoices
Cost of adult vaccine in Tianhe#	12.2	41	Health clinic reimbursement invoices

	Cost per item / batch (USD)		
Surgical gloves	0.075	228	Personal communication with research staff
Information pamphlet for free vaccination arm	20.4	1	Project research staff invoices

PIF *- pay-it-forward,* **USD** *– United States dollars*

*Hourly wages were calculated from monthly or yearly wages based on an assumption of 250 working days per year and 10 working hours per day.

†These costs were annualised over a three-year period at a discount rate of 3% as they were part of the preparatory workshop for the conception of PIF programme specifically. The training, supplies and expertise gained through these sessions are expected to be useful in future years to inform further iterations of the programme and were therefore annualised over three years.

†† It was assumed that each nurse spent 10 minutes per patient to recruit and persuade participants to be vaccinated in the pay-it-forward programme, while they spent 5 minutes per patient for the standard-of-care group, and 5 minutes per patient in the free vaccination arm.
#Only adult influenza vaccine was used in Yangshan and Tianhe, i.e. children were inoculated with the same influenza vaccine as the adults in those study sites.

Addendum: Breakdown for obtaining the total economic cost and the total financial cost of each intervention arm

<u>Total economic cost</u> of an intervention

= Start-up costs + Fixed costs + Recurrent costs

<u>Total financial cost</u> of an intervention

= Start-up costs + Fixed costs + Recurrent costs – (Payment / Donation contributions)

Costs file Figure 1: Breakdown of economic costs by category in the three intervention arms

Costs file *Table 2: Total economic costs and total financial costs by intervention arm*

Intervention arm	Total economic cost (USD)	Total financial cost (USD)
Pay-it-forward	5062	4477
Free vaccination	4665	4665
Standard-of-care	3557	2725

Note: See Table 1 for detailed breakdown of the economic and financial costs

Sensitivity analysis

One-way deterministic sensitivity analysis

The results of the one-way deterministic sensitivity analysis are shown below in the tornado diagram (Figure 2-5). Overall, they indicate the study is most sensitive to the effectiveness of each intervention in increasing vaccine uptake, which was indicated by the variable of 'vaccine uptake'. The difference

in proportions of vaccinated people between different intervention groups greatly affect the ICER by vastly increasing or decreasing the denominator for the ICER (i.e. the incremental number of vaccinations).

Other important factors that affected the ICER of the two interventions included the combined cost of all types of vaccines in all three study sites, the cost of adult vaccines in Yangshan, Zengcheng, and Tianhe respectively. For the ICER obtained using financial costs, the amount of pay-it-forward donations received was also able to shift the ICER by more than 10% above and below the original ICER estimate.

Figure 8 shows the ICER comparing pay-it-forward against standard-of-care calculated using financial costs and Figure 9 shows the ICER comparing the same two groups calculated using economic costs.

The most important factor that affected the outcome of the ICER was that of the difference in vaccine uptake between the pay-it-forward and standard-of-care groups, which shifted the upper limit of the ICER to 77.19 USD per person vaccinated, which is 2.46 times that of the original estimate of 31.29 USD. The lower limit value of the effect size of the pay-it-forward intervention compared to standard-of-care also resulted in significant improvement of the ICER to 16.56 USD per person vaccinated, halving the original estimate. This shows that the current intervention is only effective if the difference in vaccine uptake of pay-it-forward and standard-of-care groups remain substantial in future iterations of the programme and has the potential to be even more cost-effective if a higher vaccine uptake rate could be achieved in pay-it-forward.

Supplementary Figure 2: Tornado diagram showing the effect of varying different input parameters on the ICER comparing pay-it-forward against standard-of-care calculated using financial costs

Supplementary Figure 3: Tornado diagram showing the effect of varying different input parameters on the ICER comparing pay-it-forward against standard-of-care calculated using economic costs

Below figures show the ICER comparing pay-it-forward against free vaccination calculated using financial costs and the ICER comparing the same two groups calculated using economic costs.

Supplementary Figure 4: Tornado diagram showing the effect of varying different parameters on the ICER comparing pay-it-forward against free vaccination calculated using financial costs

Supplementary Figure 5: Tornado diagram showing the effect of varying different parameters on the ICER comparing pay-it-forward against free vaccination calculated using economic costs

The variables of vaccine uptake in the pay-it-forward and free vaccination groups were omitted from the tornado graphs (Figure 6-7) in the one-way DSA comparing these two groups. This was because he difference in their effect sizes (i.e. the denominator for the ICER) approached zero, and produced ICERs

which were not interpretable.

Questionnaire survey

Influenza vaccination for children and elderly people

About this study:
You are invited to participate in this influenza vaccination study. The results of this study can provide evidence for the government to develop better intervention strategies to promote influenza vaccination in China and prevent seasonal influenza among at-risk populations.

Details of this study:

You will need to fill out a questionnaire. This questionnaire will ask about your socio-demographic information and opinions towards influenza vaccine. To protect your privacy, all your answers will be transformed into digital formats and password encrypted. If you are eligible to participate in this program, out project personnel will provide you with more detailed information. To confirm whether you are qualified to participate in this program, we will first ask you a few screening questions. If you are not eligible for this program, we will not keep your survey information.

Note: If the participant is a child, the guardian will need to consent on the child's behalf and fill in the questionnaire. For the purpose of equality, only one quota is provided for each participating family, either for a child or an elderly individual.

Screening questions (all groups)

i.Which category do you belong to＿＿＿

○Caregivers of a 3-8 year-old children

○Elderly people (>=60)

ii. Your age (fill in a number) ＿＿＿

iii. Your gender（male-1, female-2）＿＿＿

iv. Have you been vaccinated against influenza in the past year?

  ○Yes (Please skip to the end of the questionnaire and submit the answer sheet)

○No

A. Basic information (all groups)

1. Ethnicity

○Han

○Other, please specify：＿＿＿＿＿＿

2. Your highest education level:

○Primary school
○Junior middle school

○High school

○Undergraduate or college

○Postgraduate or above

3. Your occupation is:

○Student

○Civil servant

○Farmer

○Ordinary workers (blue collar)

○Company staff (white collar)

○Technical personnel

○Unemployed or retired

○Other：＿＿＿＿＿＿＿＿＿＿*

4. Your personal monthly income:

○0-1000 RMB/Month

○1000-5000 RMB/Month

○5000-10,000 RMB/Month

○10,000 RMB/Month or above

5. Your current legal marriage status is:

○Unmarried

○Engaged or married

○Separated or divorced

○Widowed (skip questions 6-9)

6. Age of your partner：____

7. The highest education level of your partner:

○Primary school

○Junior middle school

○High school

○Undergraduate or college

○Postgraduate

8. The occupation of your partner is:

○Student

○Civil servant

○Farmer

○Ordinary workers (blue collar)

○Company staff (white collar)

○Technical personnel

○Unemployed or retired

○Other：__________________*

9. Your partner's personal monthly income

○0-1000 RMB/Month

○1000-5000 RMB/Month

○5000-10,000 RMB/Month

○10,000 RMB/Month or above

10 Do you have children in your family?

○Yes

○No (skip question16)

11. How many children are there in your family? (fill in your children's age and sex in chronological order, for example, Child 1, 2 years old, male-1 or female-2)

○Child 1

  Age_____

  Sex_____

○Child 2

  Age_____

  Sex_____

○Child 3

  Age_____

  Sex______

○Child 2

  Age_____

  Sex_____

○Child 2

  Age_____

  Sex_____

12. Do you have elderly people in your family?

○Yes

○No

13. How many elderly people (>=60 years) are there in your family? Age and gender?

○Elderly individual 1

  Age:

  Sex:

○Elderly individual 2

  Age:

  Sex:

B-0. "Standard of care" group

1. Main purpose of coming to the clinic？

○See a doctor for myself

○Take my child(ren) to see a doctor

○Take my child(ren) to vaccinate

○Accompany elderly family members to see a doctor

○ Body examination

○Other：____________________ *

2. The researcher has introduced the influenza vaccine. Would you like to participate in the program to vaccinate your child (or yourself if older than 60 years) today?

○Yes

○No（Please skip to the question 22）

3. Who would you like to vaccinate today?

○My Child

○Elderly family member

4.The information of the vaccination recipient?

○Sex___

○Age___

5. Has anyone in your family got seasonal flu in the past year?

○Yes

○No（Skip to the Question 24）

6.If yes, who got seasonal flu in your family?

○Children

○Elderly people

○Children's parents

7. If you want your family to vaccinate, what is the main reason?

○Children in my family are easy to get seasonable flu

○Elderly people in my family are easy to get seasonable flu

○Both my children and the old people in my family are easy to get seasonable flu

○I'm easy to get seasonable flu

○Recommended by my friends/family member

○Recommendation by HCP the clinic

○Other, please note：_______________ *

8. If you don't want to vaccinate your child or an elderly individual in your family today, why not? [multiple choices] * (if you answered "yes" to question 2, skip this item)

□I don't know enough about seasonal influenza

□I'm not sure about the effect of the influenza vaccine

□My family don't need vaccinations

□It's too cumbersome

□I'm worried about the side effects

□ I think it is too expensive

□Other, please specify: _______________*

B-1. "Pay it forward" group

1. Main purpose of coming to the clinic？

○See a doctor for myself

○Take my child(ren) to see a doctor

○Take my child(ren) to vaccinate

○Accompany elderly family members to see a doctor

○Other：_______________ *

2. The researcher has introduced the influenza vaccine and 'Pay it forward' program to you. Would you like to participate in the program to vaccinate your child (or yourself if older than 60 years) today?

○Yes

○No（Please skip to the question 27）

3. Who would you like to vaccinate today?

○My Child

○Elderly family member

4.The information of the vaccination recipient?

○Sex___

○Age___

5. Are you willing to donate some money to the next family to get the same influenza vaccination?

○Yes

○No（Skip to the Question 25）

6. How much would you like to donate to the next family?

○200 RMB (support one family to get vaccination (1elderly+1children))

○150 RMB (support 1 elderly or 3 children get vaccination)

○100 RMB (support 2 children get vaccination)

○50 RMB (support 1 children to get vaccination)

○Other amount_____

7. If you want your family to vaccinate, what is the main reason?

○Children in my family are easy to get seasonable flu

○Elderly people in my family are easy to get seasonable flu

○Both my children and the old people in my family are easy to get seasonable flu

○I'm easy to get seasonable flu

○Recommended by my friends/family member

○Recommendation by medical personnel at the clinic (irrelevant to 'Pay it forward' program)

○The 'Pay it forward' program

○Other, please note： ______________ *

8. What do you think are the benefits of the 'Pay it forward' program?

 [Multiple choice]

□Other families' donation can lower my financial burden

□I learn about influenza vaccines that can prevent flus

□Can promote more families to be vaccinated against influenza

□Can reduce the spread of influenza

□Spread love and warmth within the community

□Other： ________________________ *

9. If you don't want to vaccinate your child or an elderly individual in your family today, why not? [multiple choices] * (if you answered "yes" to question 2, skip this item)

□I don't know enough about seasonal influenza

□I'm not sure about the effect of the influenza vaccine

□My family don't need vaccinations

□It's too cumbersome

□I'm worried about the side effects

□Other, please specify: ______________ *

B-2. "Free vaccination" group

1. Main purpose of coming to the clinic？

○See a doctor for myself

○Take my child(ren) to see a doctor

○Take my child(ren) to vaccinate

○Accompany elderly family members to see a doctor

○ Body examination

○ elderly get vaccination

○Other： __________________ *

2. The researcher has introduced the influenza vaccine and free vaccination programme. Would you lik

participate in the program to vaccinate your child (or yourself if older than 60 years) today?

○Yes

○No（Please skip to the question 27）

3. Who would you like to vaccinate today?

○My Child

○Elderly family member

4.The information of the vaccination recipient?

○Sex___

○Age___

5. Has anyone in your family got seasonal flu in the past year?

○Yes

○No（Skip to the Question 25）

6.If yes, who got seasonal flu in your family?

○Children

○Elderly people

○Children's parents

7. If you want your family to vaccinate, what is the main reason?

○Children in my family are easy to get seasonable flu

○Elderly people in my family are easy to get seasonable flu

○Both my children and the old people in my family are easy to get seasonable flu

○I'm easy to get seasonable flu

○Recommended by my friends/family member

○Recommendation by HCP at the clinic

○Because the free vaccination programme

○Other, please note：_______________ *

8. If you don't want to vaccinate your child or an elderly individual in your family today, why not? [mu
choices] * (if you answered "yes" to question 2, skip this item)

□I don't know enough about seasonal influenza

□I'm not sure about the effect of the influenza vaccine

□My family don't need vaccinations

□It's too cumbersome

□I'm worried about the side effects

□Other, please specify: _______________*

C. Vaccine related information (all groups)

1. Have you heard about the flu vaccine before this program?

○Yes   ○No

2. In general, I think influenza vaccine is important. [Single choice] *

○Strong disagree   ○Disagree   ○Agree   ○Strongly agree

3. In general, I think the influenza vaccine is safe. [Single choice] *

○Strong disagree   ○Disagree   ○Agree   ○Strongly agree

4. In general, I think the influenza vaccine is effective. [Single choice] *

○Strong disagree　　　○Disagree　　　　○Agree　　　　○Strongly agree

5. Has your child ever been vaccinated against influenza?

(if there is no child in your family, please skip this question) [Single choice] *

　○Yes　　　○No

6. Have elderly people in your family ever been vaccinated against influenza

(if there are no elderly individuals in your family, please skip this question) [Single choice] *

○Yes　　　○No

7. Have you ever been hesitant about having your child or elderly family members to get the flu vaccine (except for allergies)? [Single choice] *

○Yes　　　○No

8. Have you ever postponed your child or elderly family members to get the flu vaccine (except for allergies)? [Single choice] *

○Yes　　　○No

9. Have you ever been refused to have your child or elderly family members to get the flu vaccine (except for allergies)? [Single choice] *

○Yes　　　○No

10. Have you ever heard about negative information about influenza vaccine?

○Yes　　　○No

11. Do any of your friends or relatives object to the influenza vaccination?

○Yes　　　○No

12. Have you or people around you had adverse reactions to influenza vaccination?

○Yes　　　○No

13. Do you trust the advice provided by the medical personnel in the clinic on influenza vaccine?

○Yes　　　○No

14. Is price of the vaccine a barrier for your child and/or elderly individuals in your family to get the influenza vaccine?

○Yes　　　○No